Evidence map›Paper›PMID 38409476›Full record

ArticleJournal of cardiovascular translational research2024

Circulating Proteome Analysis Identifies Reduced Inflammation After Initiation of Hemodynamic Support with Either Veno-Arterial Extracorporeal Membrane Oxygenation or Impella in Patients with Cardiogenic Shock.

Nikolaos A Diakos, Lija Swain, Shreyas Bhave, Xiaoying Qiao, Towia Libermann, Jillian Haywood, Siya Goel, Shiva Annamalai, Michele Esposito, Haval Chweich and 2 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Journal of cardiovascular translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Molecular Mechanisms of Cardiac Adaptation After Device Deployment.Journal of cardiovascular development and disease · 2025
    Review
  2. CytoSorbBiomedicines · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nikolaos A DiakosDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Lija SwainDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Shreyas BhaveDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Xiaoying QiaoDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Towia LibermannBeth Israel Deaconess Medical Center Genomics, Proteomics, Bioinformatics and Systems Biology Center, Boston, USA.
Jillian HaywoodDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Siya GoelDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Shiva AnnamalaiDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Michele EspositoDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Haval ChweichDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Anthony FaugnoDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA.
Navin K KapurDivision of Cardiology, Department of Internal Medicine, Tufts Medical Center, Boston, MA, USA. nkapur@tuftsmedicalcenter.org.ORCID 0000-0002-8302-6796

Funding

NIH HHS R01HL133215-01NIH HHS R01HL139785-01
6 · The paper itself

Abstract

In-hospital mortality associated with cardiogenic shock (CS) remains high despite the use of percutaneous assist devices. We sought to determine whether support with VA-ECMO or Impella in patients with CS alters specific components of the plasma proteome. Plasma samples were collected before device implantation and 72 h after initiation of support in 11 CS patients receiving ECMO or Impella. SOMAscan was used to detect 1305 circulating proteins. Sixty-seven proteins were changed after ECMO (18 upregulated and 49 downregulated, p < 0.05), 38 after Impella (10 upregulated and 28 downregulated, p < 0.05), and only eight proteins were commonly affected. Despite minimal protein overlap, both devices were associated with markers of reduced inflammation and increased apoptosis of inflammatory cells. In summary, ECMO and Impella are associated with reduced expression of inflammatory markers and increased markers of inflammatory cell death. These circulating proteins may serve as novel targets of therapy or biomarkers to tailor AMCS use.

Indexed as

BiomarkersExtracorporeal Membrane OxygenationHeart-Assist DevicesHemodynamicsInflammation MediatorsProteomeProteomicsShock, CardiogenicAdultAgedApoptosisBlood ProteinsFemaleHumansInflammationMaleBiomarkersBlood ProteinsInflammation MediatorsProteomeCardiogenic shockHeart failureInflammationMechanical circulatory supportProteomics

Identifiers

PMID38409476

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.